An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Trial Status: Complete
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
Inclusion Criteria
- histologically or cytologically proven diagnosis of non-small cell lung cancer
- positive for the ALK fusion gene (test provided by a central laboratory)
- must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
- tumors must be measurable
Exclusion Criteria
- prior treatment with PF-02341066
- current treatment in another clinical trial
Arizona
Scottsdale
Mayo Clinic in Arizona
Status: WITHDRAWN
California
Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: COMPLETED
Orange
UC Irvine Health / Chao Family Comprehensive Cancer Center
Status: COMPLETED
Palo Alto
Stanford Cancer Institute Palo Alto
Status: COMPLETED
Sacramento
University of California Davis Comprehensive Cancer Center
Status: COMPLETED
San Diego
UC San Diego Medical Center - Hillcrest
Status: COMPLETED
Colorado
Aurora
University of Colorado Hospital
Status: COMPLETED
Connecticut
New Haven
Yale University
Status: COMPLETED
Florida
Tampa
Moffitt Cancer Center
Status: COMPLETED
Georgia
Atlanta
Emory University Hospital / Winship Cancer Institute
Status: ADMINISTRATIVELY_COMPLETE
Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Status: COMPLETED
Indiana
Indianapolis
Indiana University / Melvin and Bren Simon Cancer Center
Status: COMPLETED
Maryland
Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: COMPLETED
Massachusetts
Boston
Beth Israel Deaconess Medical Center
Status: COMPLETED
Dana-Farber Cancer Institute
Status: COMPLETED
Massachusetts General Hospital Cancer Center
Status: COMPLETED
Michigan
Detroit
Wayne State University / Karmanos Cancer Institute
Status: ADMINISTRATIVELY_COMPLETE
Missouri
Saint Louis
Siteman Cancer Center at Washington University
Status: COMPLETED
Nebraska
Omaha
University of Nebraska Medical Center
Status: COMPLETED
New Hampshire
Lebanon
Dartmouth Hitchcock Medical Center
Status: COMPLETED
New York
New York
Memorial Sloan Kettering Cancer Center
Status: COMPLETED
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: COMPLETED
North Carolina
Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: COMPLETED
Ohio
Cleveland
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Status: COMPLETED
Columbus
Ohio State University Comprehensive Cancer Center
Status: COMPLETED
Oregon
Portland
OHSU Knight Cancer Institute
Status: COMPLETED
Pennsylvania
Philadelphia
Fox Chase Cancer Center
Status: CLOSED_TO_ACCRUAL_AND_INTERVENTION
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: COMPLETED
Tennessee
Nashville
Vanderbilt University / Ingram Cancer Center
Status: COMPLETED
Texas
Houston
M D Anderson Cancer Center
Status: COMPLETED
Washington
Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: COMPLETED
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Pfizer Inc
- Primary ID A8081007
- Secondary IDs NCI-2010-00112, 2009-012595-27
- Clinicaltrials.gov ID NCT00932893